FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy and Safety of Extended-Release Acetazolamide Capsules for the Prevention of Acute Mountain Sickness: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial. PMID 40955751 · High Alt Med Biol · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Complementary Use of Probiotics and Their Antimicrobial Proteins in Brucellosis: A Comprehensive Review of Mechanisms and Clinical Benefits. PMID 40864417 · Probiotics Antimicrob Proteins · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of a cognitive-behavioral digital therapeutic on psychosocial outcomes in cancer patients: A randomized controlled trial. PMID 40785239 · J Health Psychol · 2026-Mar The study meets criteria for being an oncology, human, randomized, original-result report, but is excluded because the intervention is non-drug and the primary endpoints are not time-to-event efficacy measures. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study. PMID 40738276 · Clin Gastroenterol Hepatol · 2026-Mar The record describes a Phase 3 randomized trial of upadacitinib for Crohn's disease, which is not an oncologic malignancy. The primary endpoints (CDAI clinical remission and endoscopic response at week 52) are categorical outcomes at a fixed time, not time-to-event endpoints such as OS, PFS, DFS, or time-to-event analyses (e.g., Kaplan-Meier curves, hazard ratios for time to event). Therefore, it does not meet the cohort's inclusion criteria for an oncology trial with a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A qualitative examination of cognitive behavioral therapy strategies and health management content to reduce fear of cancer recurrence among breast cancer survivors: Results from the FoRtitude study. PMID 40721359 · J Health Psychol · 2026-Mar The record describes a randomized trial of non-drug interventions (cognitive behavioral therapy vs. health management content) for fear of cancer recurrence in breast cancer survivors. While it is an oncology human randomized trial with original results, it is ineligible because it lacks a Phase III designation, lacks a time-to-event efficacy endpoint (e.g., OS, PFS), and lacks a drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Lumen-Apposing Stents With or Without Pigtail in Endosonography-Guided Biliary Drainage for Malignant Distal Biliary Obstruction. PMID 40701486 · Clin Gastroenterol Hepatol · 2026-Mar 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Enhancing the Quality of Hospice Shared Care for End-Stage Malignant Tumor Patients: A Structure-process-outcome Three-Dimensional Quality Evaluation Model. PMID 40403769 · Am J Hosp Palliat Care · 2026-Mar The study is an oncology randomized controlled trial with original results, but it does not meet the key eligibility criteria: 1) The endpoint is quality of life, spiritual well-being, psychological distress, and patient satisfaction, not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). 2) The intervention is a hospice care model, not a drug-containing intervention. 3) The phase is not specified as Phase III or a definitive Phase II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial. PMID 40319177 · Prostate Cancer Prostatic Dis · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK. PMID 40140551 · Prostate Cancer Prostatic Dis · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Phase III study of Phlai capsules in the treatment of allergic rhinitis: A randomized, double-blind, placebo-controlled trial. PMID 37302097 · Asian Pac J Allergy Immunol · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comprehensive Safety and Efficacy Evaluation of Immunotherapy Combination Approaches Versus Tyrosine Kinase Inhibitor Monotherapy as First-Line Treatment of Hepatocellular Carcinoma: A Network and Individual Patient Data (IPD) Meta-Analysis. PMID 42449661 · Cancers (Basel) · 2026-Jun-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of reinforced pancreaticojejunostomy with or without tissue adhesive glue modified cyanoacrylate following pancreaticoduodenectomy: a randomized controlled clinical trial. PMID 42381068 · World J Surg Oncol · 2026-Jun-30 The record is an oncology randomized controlled trial in humans with original primary results, but it is excluded because the phase is not established as definitive (Phase III/IIIb or Phase II/III), the intervention is a surgical technique/adjunct (tissue adhesive) rather than a systemic drug therapy, and the primary efficacy endpoint is a surgical complication rate (POPF), not a time-to-event endpoint like OS, PFS, DFS, etc. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Multitask learning of longitudinal circulating biomarkers and clinical outcomes: identification of optimal machine-learning and deep-learning models. PMID 42381014 · BMC Med Inform Decis Mak · 2026-Jun-30 This is a secondary analysis using data from the SQUIRE trial to evaluate machine learning methods for predicting survival from biomarkers. It is not the original formal result report of the trial's primary or key secondary efficacy endpoint. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study. PMID 42380630 · Nat Cancer · 2026-Jun-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin Lymphoma. PMID 42379221 · Blood Adv · 2026-Jun-30 The record describes a secondary, prognostic analysis of imaging biomarkers (Deauville score) within cohorts from randomized Phase III trials, but it is not a primary report of the trial's drug intervention efficacy. The analysis compares prognostic subgroups, not treatment arms. Therefore, it does not meet the criterion for being an original formal-result report of a drug intervention. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial. PMID 42379209 · Lancet Infect Dis · 2026-Jun-30 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis. PMID 42378247 · Blood · 2026-Jun-30 The study is a randomized, Phase 3 oncology trial with a drug intervention, but its primary and secondary efficacy endpoints (SVR, TSS change) are not time-to-event (e.g., OS, PFS, DFS) outcomes. No evidence of Kaplan-Meier analysis or Hazard Ratio is provided in the abstract. |
H
|
仅历史库存 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison. PMID 42316774 · Expert Rev Hematol · 2026-Jun-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-term safety and efficacy of voclosporin in Asian patients with lupus nephritis: A post hoc analysis of the AURORA 2 trial. PMID 41410387 · Mod Rheumatol · 2026-Jun-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparison of the Effects of Intraoperative Pectoral Nerve Block and Local Wound Infiltration in Pain Management for Breast Cancer Surgery: A Randomized Controlled Trial. PMID 42376719 · J Perianesth Nurs · 2026-Jun-29 The study is a randomized trial in oncology patients, but it evaluates a local anesthetic technique for postoperative pain, not a drug intervention with a cancer-related time-to-event efficacy endpoint. It is excluded due to lack of qualifying drug intervention and time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database. PMID 42373605 · Blood Cancer J · 2026-Jun-29 The report is a secondary analysis of an observational database, not the primary report of a randomized controlled trial. While it discusses a randomized Phase III trial (VERONA) for context, the analysis presented is of non-randomized treatment groups (HMA monotherapy vs HMA/VEN) from a real-world cohort. Therefore, it does not meet the requirement for an original formal-result report of a randomized trial. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of biosimilar aflibercept MYL-1701P in diabetic macular oedema: 20-week extension results following the INSIGHT pivotal trial. PMID 42373197 · BMJ Open Ophthalmol · 2026-Jun-29 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Chinese herbal medicine Xiangsu Hewei Granules in treating non-erosive gastroesophageal reflux disease with liver stomach stagnation heat syndrome: A multicentre, randomized, double-blind, placebo-controlled trial. PMID 42372807 · J Ethnopharmacol · 2026-Jun-29 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase 3 trial. PMID 42372782 · Lancet Rheumatol · 2026-Jun-29 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies. PMID 42372625 · Vaccine · 2026-Jun-29 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A Relative Bioavailability Study of Vepdegestrant Tablets in Healthy Adult Participants. PMID 42371393 · Eur J Drug Metab Pharmacokinet · 2026-Jun-29 The study is a Phase 1, randomized, open-label, crossover pharmacokinetic/bioequivalence study in healthy adults. Although it involves an oncology drug (vepdegestrant) for a cancer indication, the trial is Phase I, the primary endpoints are pharmacokinetic (AUC, Cmax), and it does not assess time-to-event efficacy outcomes (e.g., OS, PFS, DFS, HR, Kaplan-Meier) in cancer patients. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort of definitive efficacy trials. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Controlled Trial (NUPAT-01). PMID 42370451 · J Hepatobiliary Pancreat Sci · 2026-Jun-29 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Tenecteplase versus standard care in patients with acute basilar artery occlusion: a multi-centre, prospective, randomised, open-label, blinded endpoint, phase 3, controlled trial. PMID 41151803 · Stroke Vasc Neurol · 2026-Jun-29 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Any impact of pre-operative radiotherapy on renal function in retroperitoneal soft tissue sarcomas? A secondary ancillary analysis of the EORTC 62092 STRASS 1 trial. PMID 42364816 · Radiother Oncol · 2026-Jun-27 干预为非药物单独策略,未满足药物干预要求。 |
H
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| JAAD Game Changers: "Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial". PMID 42364776 · J Am Acad Dermatol · 2026-Jun-27 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older: Evidence From the HPV FOCAL Randomized Controlled Trial. PMID 42363777 · Int J Cancer · 2026-Jun-27 The record does not meet all eligibility criteria: while it is an oncology-related, human, randomized trial with a time-to-event endpoint and original results, it lacks a drug-containing intervention and explicit Phase III/IIIb or Phase II/III evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. PMID 42330995 · Lancet · 2026-Jun-27 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration from China: 48-week results from the PULSAR trial. PMID 42363252 · Int J Retina Vitreous · 2026-Jun-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immersive virtual reality with synchronous neurostimulation for upper-limb recovery after stroke: a randomized feasibility trial. PMID 42362865 · Nat Med · 2026-Jun-26 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Beyond the "cold" barrier: Redefining the clinical paradigm of immune checkpoint inhibitor therapy in ovarian cancer. PMID 42362076 · Crit Rev Oncol Hematol · 2026-Jun-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial. PMID 42361317 · Eur J Heart Fail · 2026-Jun-26 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial. PMID 42361276 · J Clin Oncol · 2026-Jun-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial. PMID 42360803 · Clin Cancer Res · 2026-Jun-26 This is a pre-specified biomarker subgroup analysis of the ENZAMET trial, not the primary result report of the randomized Phase III trial itself. The primary trial results are reported elsewhere. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Global Trends in Surgical Oncology Deescalation Phase III Randomized Trials. PMID 42360646 · Ann Surg Oncol · 2026-Jun-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study. PMID 42360473 · J Neurol · 2026-Jun-26 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. PMID 42360104 · Clin Cancer Res · 2026-Jun-26 The record reports a secondary analysis (identifying variables associated with early detriment) from two Phase III randomized trials (CheckMate 227 and 9LA). While the underlying trials are eligible, this specific publication is not a primary report of an original efficacy endpoint. The abstract focuses on rapid progression rates and biomarker associations, not on presenting Kaplan-Meier survival curves or hazard ratios for the primary trial endpoints. Therefore, it does not meet the criterion of being an original formal-result report with a primary/key secondary time-to-event efficacy endpoint. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Patient-led, home-based follow-up for colorectal cancer: the DISTANCE multicentre stepped-wedge cluster-randomised trial. PMID 42359543 · Br J Surg · 2026-Jun-26 The record is an oncology, human, randomized trial with results, but it is excluded because it is not a Phase III/IIIb or definitive Phase II/III trial, does not contain a drug-containing intervention (it is a non-drug follow-up model comparison), and does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint was hospital contacts, and secondary endpoints included QoL and distress metrics. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for the Use of Radiation in the Prevention and Treatment of Heterotopic Ossification (HO). PMID 42357986 · Am J Clin Oncol · 2026-Jun-26 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning. PMID 42348666 · Curr Opin Hematol · 2026-Jun-26 The record is a journal article review article (publication_type: Journal Article) summarizing mechanistic and clinical data on factor XIa inhibitors. It is not an original result report of a Phase III/IIIb or Phase II/III randomized trial. The review mentions oncology (cancer-associated thrombosis) as a potential indication, but does not report results of an oncology trial with a time-to-event efficacy endpoint. It does not contain original Kaplan-Meier data, HR, or other time-to-event results for an oncology indication. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Para-Aortic Lymph Node Staging and Oncologic Outcomes in Locally Advanced Cervical Cancer: A Narrative Review. PMID 42449603 · Cancers (Basel) · 2026-Jun-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018-2025: A cross-sectional analysis. PMID 42442095 · Eur J Cancer · 2026-Jun-25 The record is a cross-sectional review/meta-analysis of multiple trials, not an original primary report of a single trial. Therefore, it is excluded. |
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32. PMID 42360727 · JNCI Cancer Spectr · 2026-Jun-25 The record describes a secondary/prognostic biomarker analysis within a large randomized trial (MA.32). While the trial itself may be a definitive Phase III study, the specific report provided does not explicitly state the trial phase, and its primary focus is not on evaluating a drug intervention's efficacy but on the prognostic value of CA 15-3. Therefore, it fails the 'drug intervention' and 'explicit phase' criteria for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Nanoencapsulated Sirolimus plus Pegadricase: Results from the Randomized, Placebo-Controlled Phase 3 Trials. PMID 42351343 · Arthritis Rheumatol · 2026-Jun-25 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Strengthening cancer prevention in european schools: a randomized controlled trial of digital interventions in adolescents: the SUNRISE program. PMID 42351094 · BMC Public Health · 2026-Jun-25 The record describes a protocol for a cluster-randomized controlled trial of a digital health intervention for cancer prevention in adolescents. It is not a report of a completed Phase II/III or Phase III/IIIb randomized trial in human malignant neoplasm patients with a drug intervention and a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of the established ASAS definition and preliminary proposed data-driven cut-offs for inflammatory and structural MRI lesions in the sacroiliac joints for eligibility of patients with nonradiographic axial spondyloarthritis in clinical trials. PMID 42350183 · Ann Rheum Dis · 2026-Jun-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |